Multifarious proteomic signatures and regional heterogeneity in glioblastomas

To investigate the underlying intratumoral diversity of molecular profiles in glioblastomas, a proteomic approach was introduced to compare samples from regions of different histological grade. Using two-dimensional gel electrophoresis (2DE) with matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), we compared prospectively collected tissue samples of different histological grade areas of three glioblastoma patients. Consistent results showing relatively high expression of ubiquitin carboxyl-terminal esterase L1 in low-histological-grade areas (Grade 2 > Grades 3 and 4) and high expression of transthyretin in high-histological-grade areas (Grade 2 < Grades 3 and 4) were demonstrated. These results were confirmed by western blot (WB) analysis and immunohistochemical staining. This study provided the evidence of multifarious proteomic signatures according to regional and histological heterogeneity in glioblastomas.Diehn M, 2008, P NATL ACAD SCI USA, V105, P5213, DOI 10.1073/pnas.0801279105Whittle IR, 2007, BRIT J NEUROSURG, V21, P576, DOI 10.1080/02688690701721691Glanz C, 2007, NEUROPATH APPL NEURO, V33, P440, DOI 10.1111/j.1365-2990.2007.00832.xSetsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007Richardson SJ, 2007, INT REV CYTOL, V258, P137, DOI 10.1016/S0074-7696(07)58003-4Seliger B, 2007, CLIN CANCER RES, V13, P27, DOI 10.1158/1078-0432.CCR-06-0824Necesalova E, 2007, NEOPLASMA, V54, P212Van Meter T, 2006, DIAGN MOL PATHOL, V15, P195Kassem NA, 2006, AM J PHYSIOL-REG I, V291, pR1310, DOI 10.1152/ajpregu.00789.2005Lee YM, 2006, CANCER SCI, V97, P1205, DOI 10.1111/j.1349-7006.2006.00320.xFevre-Montange M, 2006, J NEUROPATH EXP NEUR, V65, P1004Kleinschmidt-DeMasters BK, 2006, BRAIN PATHOL, V16, P273Shen H, 2006, APOPTOSIS, V11, P1049, DOI 10.1007/s10495-006-6303-8Yamashita K, 2006, CANCER RES, V66, P3921, DOI 10.1158/0008-5472.CAN-05-1511Aghi M, 2005, CLIN CANCER RES, V11, P8600, DOI 10.1158/1078-0432.CCR-05-0713Mandelker DL, 2005, CANCER RES, V65, P4963Odreman F, 2005, J PROTEOME RES, V4, P698, DOI 10.1021/pr0498180Iwadate Y, 2005, INT J ONCOL, V26, P993Chumbalkar VC, 2005, PROTEOMICS, V5, P1167, DOI 10.1002/pmic.200401202Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535Otsuki T, 2004, BRIT J HAEMATOL, V127, P292, DOI 10.1111/j.1365-2141.2004.05205.xHibi K, 2004, ANTICANCER RES, V24, P3731Furuta M, 2004, ONCOGENE, V23, P6806, DOI 10.1038/sj.onc.1207770Zhang Z, 2004, CANCER RES, V64, P5882Iwadate Y, 2004, CANCER RES, V64, P2496Takano T, 2004, EUR J CANCER, V40, P614, DOI 10.1016/j.ejca.2003.11.016Ovaa H, 2004, P NATL ACAD SCI USA, V101, P2253, DOI 10.1073/pnas.0308411100Schwartz SA, 2004, CLIN CANCER RES, V10, P981SUZUKI T, 2004, BRAIN TUMOR PATHOL, V21, P27Hobbs SK, 2003, J MAGN RESON IMAGING, V18, P530, DOI 10.1002/jmri.10395Walker C, 2003, CLIN CANCER RES, V9, P4841Takase T, 2003, HEPATO-GASTROENTEROL, V50, P1278Sato N, 2003, CANCER RES, V63, P3735Campbell I, 2003, RAPID PROTOTYPING J, V9, P5Yamazaki T, 2002, CLIN CANCER RES, V8, P192Palha JA, 2002, NEUROSCIENCE, V113, P837Brichory F, 2001, CANCER RES, V61, P7908Rosas SLB, 2001, CANCER LETT, V170, P73Mariani L, 2001, CLIN CANCER RES, V7, P2480Gavioli R, 2001, NAT CELL BIOL, V3, P283Loeper S, 2001, CYTOGENET CELL GENET, V94, P1Tezel E, 2000, CLIN CANCER RES, V6, P4764Shuangshoti S, 2000, ONCOL REP, V7, P113Tynninen O, 1999, INVEST RADIOL, V34, P427Hibi K, 1998, CANCER RES, V58, P5690Sugahara T, 1998, AM J ROENTGENOL, V171, P1479Harada K, 1998, CANCER RES, V58, P4694ALBRECHT S, 1995, NEUROPATH APPL NEURO, V21, P399ALKATIB AM, 1995, CELL GROWTH DIFFER, V6, P211TOVI M, 1994, ACTA RADIOL, V35, P495KUNISHIO K, 1991, NEUROL MED CHIR, V31, P859WILKINSON KD, 1989, SCIENCE, V246, P670EARNEST F, 1988, RADIOLOGY, V166, P823